Market Access, Pricing, Licensing
Ted has over 20 years of experience in the pharmaceutical industry and is currently vice president at LatticePoint Consulting, working with early-stage companies, including various rare diseases. Ted is an independent director of Promethera Biosciences, a pre-commercial-stage cell-therapy company based in Belgium and is a Board Member for the Utah Chapter of the National Association for Corporate Directors (NACD).
Expertise
- Pricing, market access, business development, licensing, and valuation
- Publishing on pricing reform and cell and gene therapies
Experience
- Prior to LatticePoint, he was vice president of Market Access for Genzyme’s Rare Disease Business Unit and was Pfizer’s Head of Market Access for the Primary Care Business Unit.
- International finance work at Schering-Plough
- He has a bachelor’s in science degree in accounting from Villanova University, a master’s degree in International Affairs from The Fletcher School at Tufts University, and an MBA from NYU Stern